Skip to main content

EMA Panel Recommends Approval of Loxapine for Agitation


An advisory panel to the European Medicines Agency (EMA) has recommended the approval of loxapine ( Adasuve, Alexa UK Ltd) for the rapid control of agitation in adult patients with bipolar disorder or schizophrenia.
On Thursday, the Committee for Medicinal Products for Human Use announced it had adopted a positive opinion on the drug and recommended that it be granted marketing authorization.
A psycholeptic antipsychotic, its efficacy is thought to be mediated through high-affinity antagonist of dopamine D2 receptors and serotonin 5-HT2A receptors.
Loxapine binds with noradrenergic, histaminergic, and cholinergic receptors. Its interaction with these systems may influence the spectrum of its pharmacologic effects associated with calming effects and suppression of aggressive behavior.
According to the committee's written opinion, the benefits of the drug are its "ability to rapidly reduce the agitation in mild to moderate patients with schizophrenia or bipolar disorder. In these patients decreased agitation was evident 10 minutes after the first dose, the first assessment time, and at all subsequent assessments during the 24 hour evaluation period, both for the 4.5 mg and 9.1 mg doses. About a quarter to nearly half of the patients needed a second dose after 2 hours to reach a satisfactory effect."
The most common side effects of the drug include dysgeusia, sedation/somnolence, and dizziness. Bronchospasm was reportedly uncommon, but in individuals with active airways disease, it was commonly reported and often required treatment with a short-acting beta-agonist bronchodilator.
The committee notes that a "pharmacovigilance plan" for the drug will be implemented as part of the marketing authorization.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more